Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PI3K p110γ is the catalytic subunit of the class IB phosphoinositide 3-kinase, encoded by the PIK3CG gene. PI3Kγ forms heterodimers with regulatory subunits p101 or p84, and is uniquely activated downstream of G protein–coupled receptors, integrating signals from Gβγ subunits and Ras to modulate cellular signaling. Its central role in leukocyte migration, inflammation, cardiac function, and cancer progression makes it a key therapeutic target, though safety concerns exist due to its broad involvement in immune and cardiovascular pathways. The complex structure of p110γ enables nuanced regulation and multiple routes for pharmacological inhibition, including ATP-competitive and allosteric mechanisms[1][2][3][4][5][6].
ATP-competitive inhibition of the lipid kinase domain; Allosteric inhibition of regulatory subunit interface or kinase domain dynamics (e.g., nanobodies); Modulation of upstream interactions (disruption of Gβγ or Ras binding)
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phosphoinositide 3-kinase catalytic subunit gamma (PI3K p110γ).